Literature DB >> 23478959

Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.

Cristina García-de-la-Mària1, Juan M Pericas, Ana Del Río, Ximena Castañeda, Xavier Vila-Farrés, Yolanda Armero, Paula A Espinal, Carlos Cervera, Dolors Soy, Carlos Falces, Salvador Ninot, Manel Almela, Carlos A Mestres, Jose M Gatell, Jordi Vila, Asuncion Moreno, Francesc Marco, Jose M Miró.   

Abstract

The development of high-level daptomycin resistance (HLDR; MIC of ≥ 256 mg/liter) after exposure to daptomycin has recently been reported in viridans group streptococcus (VGS) isolates. Our study objectives were as follows: to know whether in vitro development of HLDR after exposure to daptomycin was common among clinical isolates of VGS and Streptococcus bovis; to determine whether HLDR also developed during the administration of daptomycin to treat experimental endocarditis caused by the daptomycin-susceptible, penicillin-resistant Streptococcus mitis strain S. mitis 351; and to establish whether combination with gentamicin prevented the development of HLDR in vitro and in vivo. In vitro studies were performed with 114 VGS strains (mitis group, 92; anginosus group, 10; mutans group, 8; and salivarius group, 4) and 54 Streptococcus bovis strains isolated from 168 consecutive patients with infective endocarditis diagnosed between 1995 and 2010. HLDR was only observed after 24 h of exposure to daptomycin in 27% of the mitis group, including 27% of S. mitis isolates, 47% of S. oralis isolates, and 13% of S. sanguis isolates. In our experimental model, HLDR was detected in 7/11 (63%) and 8/12 (67%) isolates recovered from vegetations after 48 h of daptomycin administered at 6 mg/kg of body weight/24 h and 10 mg/kg/24 h, respectively. In vitro, time-kill experiments showed that daptomycin plus gentamicin was bactericidal against S. mitis 351 at tested concentrations of 0.5 and 1 times the MIC and prevented the development of HLDR. In vivo, the addition of gentamicin at 1 mg/kg/8 h to both daptomycin arms prevented HLDR in 21 out of 23 (91%) rabbits. Daptomycin plus gentamicin was at least as effective as vancomycin plus gentamicin. In conclusion, HLDR develops rapidly and frequently in vitro and in vivo among mitis group streptococci. Combining daptomycin with gentamicin enhanced its activity and prevented the development of HLDR in most cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478959      PMCID: PMC3632914          DOI: 10.1128/AAC.01921-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Clinical experience with daptomycin for outpatient parenteral antibiotic therapy.

Authors:  Julius Larioza; Amy Girard; Richard B Brown
Journal:  Am J Med Sci       Date:  2011-12       Impact factor: 2.378

2.  Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.

Authors:  Jennifer M Streit; Judith N Steenbergen; Grace M Thorne; Jeffrey Alder; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2005-02-18       Impact factor: 5.790

3.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

Review 4.  Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy.

Authors:  C S Levy; P Kogulan; V J Gill; M B Croxton; J G Kane; D R Lucey
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

5.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

Review 6.  Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.

Authors:  F Kate Gould; David W Denning; Tom S J Elliott; Juliet Foweraker; John D Perry; Bernard D Prendergast; Jonathan A T Sandoe; Michael J Spry; Richard W Watkin
Journal:  J Antimicrob Chemother       Date:  2011-11-14       Impact factor: 5.790

7.  Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics.

Authors:  E Presterl; A J Grisold; S Reichmann; A M Hirschl; A Georgopoulos; W Graninger
Journal:  J Antimicrob Chemother       Date:  2004-11-24       Impact factor: 5.790

8.  Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora.

Authors:  Helena Seppälä; Marjo Haanperä; Mohammad Al-Juhaish; Helinä Järvinen; Jari Jalava; Pentti Huovinen
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

9.  Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease.

Authors:  K Westling; I Julander; P Ljungman; A Heimdahl; A Thalme; C E Nord
Journal:  Clin Microbiol Infect       Date:  2004-10       Impact factor: 8.067

10.  Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart.

Authors:  P K Garrison; L R Freedman
Journal:  Yale J Biol Med       Date:  1970-06
View more
  24 in total

Review 1.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

Review 2.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

3.  Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.

Authors:  Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Nagendra N Mishra; Jose M Miro; Cesar A Arias; Truc T Tran; Paul M Sullam; Arnold S Bayer; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis.

Authors:  Truc T Tran; Nagendra N Mishra; Ravin Seepersaud; Lorena Diaz; Rafael Rios; An Q Dinh; Cristina Garcia-de-la-Maria; Michael J Rybak; Jose M Miro; Samuel A Shelburne; Paul M Sullam; Arnold S Bayer; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

5.  Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Authors:  C Garcia-de-la-Maria; Y Q Xiong; J M Pericas; Y Armero; A Moreno; N N Mishra; M J Rybak; T T Tran; C A Arias; P M Sullam; A S Bayer; J M Miro
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies.

Authors:  Brianne Zapata; Danya N Alvarez; Sabrina Farah; Cristina Garcia-de-la-Maria; Jose M Miro; George Sakoulas; Arnold S Bayer; Nagendra N Mishra
Journal:  Curr Microbiol       Date:  2018-04-12       Impact factor: 2.188

7.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

8.  Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.

Authors:  Juan M Pericàs; Ruvandhi Nathavitharana; Cristina Garcia-de-la-Mària; Carles Falces; Juan Ambrosioni; Manel Almela; Javier García-González; Eduard Quintana; Francesc Marco; Asunción Moreno; Arnold S Bayer; José M Miró; Adolf W Karchmer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

9.  Genetic characterization and role in virulence of the ribonucleotide reductases of Streptococcus sanguinis.

Authors:  DeLacy V Rhodes; Katie E Crump; Olga Makhlynets; Melanie Snyder; Xiuchun Ge; Ping Xu; JoAnne Stubbe; Todd Kitten
Journal:  J Biol Chem       Date:  2013-12-31       Impact factor: 5.157

Review 10.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.